Ignite Creation Date:
2024-05-06 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06238752
Status:
COMPLETED
Last Update Posted:
2024-02-02
First Post:
2024-01-24
Brief Title:
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
Sponsor:
Renmin Hospital of Wuhan University
Organization:
Renmin Hospital of Wuhan University
Study Overview
Official Title:
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced Gastric and Gastroesophageal JunctionGGEJ Adenocarcinoma Patients With Poor Prognosis A Prospective Exploratory Study
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RENMIN-213
Brief Summary:
In this clinical study investigators explore the efficacy and safety of a combination therapy regimen with antiangiogenic agent apatinib ICI tislelizumab and chemotherapy capecitabine Oxaliplatin XELOX as first-line treatment for HER2-negative advanced GGEJ cancer patients with signet ring cell carcinoma or peritoneal metastasis
Detailed Description:
Patients received 8 cycles of apatinib 250 mg qd d1-14 tislelizumab 200 mg d1 and oxaliplatin 130 mgm2 d1 plus oral capecitabine 1000 mgm2 bid d1-14 every 3 weeks with a maintenance therapy with apatinib plus tislelizumab for a maximum of 1 year Homogeneous patients receiving ICIs combined with chemotherapy at the same time were deemed as the control group for efficacy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None